ADC THERAPEUTICS SA (ADCT)

CH0499880968 - Common Stock

0.861  -0.05 (-5.38%)

ADC THERAPEUTICS SA

NYSE:ADCT (9/27/2023, 12:21:07 PM)

0.861

-0.05 (-5.38%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)11-06 2023-11-06/amc
Ins OwnersN/A
Inst Owners56.25%
Market Cap69.43M
Shares80.64M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts77.14
IPO05-15 2020-05-15
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADCT Daily chart

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 317 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

Company Info

ADC THERAPEUTICS SA

Biopole, route de la Corniche 3B

Epalinges VAUD 1066

P: 41216530200.0

CEO: Christopher Martin

Employees: 317

Website: https://adctherapeutics.com/

ADCT News

News Image7 days ago - Market News VideoWednesday Sector Leaders: Drugs, Precious Metals
News Image15 days ago - Seeking AlphaADC Therapeutics tumbles after withdrawing 2023 revenue guidance (NYSE:ADCT)

Shares of ADC Therapeutics (ADCT) tumbled 3.4% on Tuesday after the company disclosed that it was withdrawing its 2023 revenue outlook.ADT added that it was withdrawing its guidance...

News Image22 days ago - ADC Therapeutics SAADC Therapeutics to Participate in September Investor Conferences
News Image22 days ago - ADC Therapeutics SAADC Therapeutics nimmt im September an Anlegerkonferenzen teil

LAUSANNE, Schweiz, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass Ameet Mallik, Chief Executive...

News Image22 days ago - ADC Therapeutics SAADC Therapeutics to Participate in September Investor Conferences

LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer,...

News Imagea month ago - ADC Therapeutics SAADC Therapeutics gibt auf der elften Jahrestagung der Society of Hematologic Oncology (SOHO 2023) Updates zu den klinischen Studienprogrammen mit ZYNLONTA® LOTIS bekannt

LOTIS-5: Aktualisierte Sicherheitsergebnisse der Phase-3-Studie zeigen eine 80%ige ORR, 50%ige CR-Rate und eine mediane DoR von 8 Monaten ohne neue...

ADCT Twits

Here you can normally see the latest stock twits on ADCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example